Biogen Inc. looked for a broader label in connection with potential approval of the spinal muscular atrophy (SMA) candidate, nusinersen, after reporting with Ionis Pharmaceuticals Inc. that the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback